Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Kakao Healthcare, Sanofi partner to develop AI solutions using medical data for disease diagnosis
Research collaboration, AI/ML, rare disease, digital health - Read more

Amgen's subcutaneous Tepezza (teprotumumab) meets Ph3 endpoints for thyroid eye disease treatment
Protein therapy, autoimmune, monoclonal antibody, thyroid eye disease, subcutaneous delivery, IGF-1 receptor - Read more

Praxis Precision Medicines' elsunersen shows 77% seizure reduction in Ph1/2 trial for SCN2A developmental and epileptic encephalopathy
Gene therapy, neurological, antisense oligonucleotide, developmental and epileptic encephalopathy, SCN2A, pediatric - Read more

Akeso presents Ph2 data on cadonilimab bispecific antibody combo in PD-L1 inhibitor-resistant non-small cell lung cancer
Antibody, cancer, bispecific antibody, non-small cell lung cancer, PD-L1, combination therapy - Read more

ABION presents preclinical data showing ABN202 interferon-beta antibody conjugate outperforms TROP2-targeting antibody-drug conjugates
Antibody-drug conjugate, cancer, interferon-beta fusion, TROP2 target, solid tumors, immuno-oncology - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Stipple Bio emerges from stealth with $100M Series A to develop tumor-specific epitope-targeting ADCs
Antibody-drug conjugate, oncology, strategic, major transaction - Read more

Renovare Therapeutics launches from stealth with $33.5M ARPA-H collaboration to advance osteoarthritis regenerative therapies
Regenerative therapy, osteoarthritis, strategic, major transaction - Read more

Mesoblast reports Ryoncil net sales of $30.3M in March quarter, approaching $100M first-year revenue
Cell therapy, graft-versus-host disease, financial, revenue impact - Read more

SpectronRx raises $85M financing to expand medical isotope production and CDMO capabilities
Radiopharmaceutical, CDMO, medical isotope production, manufacturing services - Read more

Beacon Biosignals raises $11M Series B extension, scalable at-home EEG analytics
Neurological, AI/ML platform, biomarker discovery, wearable technology - Read more

Apnimed raises $150M debt financing for sleep apnea therapy commercial launch
Sleep apnea, small molecule, clinical-stage, neurological - Read more

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9B in “surprising” acquisition, gaining rare obesity disorder drug Vykat XR
Small molecule, rare disease, strategic, major transaction - Read more

Ascendis Pharma receives FDA orphan drug exclusivity and launches YUVIWEL for achondroplasia treatment
Prodrug, rare disease, regulatory, strategic, revenue impact - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Biogen expects $34M Q1 hit from acquired R&D, upfront and milestone expenses
Financial, operational, strategic, investment - Read more

Kennedy gains direct control over CDC vaccine panel through renewed ACIP charter bypassing expert vetting
Vaccine, infectious disease, regulatory, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here